Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Open | $77.00 |
Close | $77.61 |
Volume / Avg. | 845.89K / 996.19K |
Day Range | $76.80 - $78.15 |
52 Wk Range | 45.50 - 84.89 |
Market Cap | $8.20B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 63 |
Short Interest | 2.63% |
Days to Cover | 5.74 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Intra-Cellular Therapies (NASDAQ:ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
Intra-Cellular Therapies has a consensus price target of $92.73.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $77.61 last updated September 20, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q3 earnings are confirmed for Thursday, October 31, 2024.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.